pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
JOHNSON & JOHNSON ($JNJ) · news · pharmadog
← back to JOHNSON & JOHNSON
News mentioning $JNJ
164
stories
3d
BMO most bullish on Merck's, bearish on BMS’ plans to contend with patent cliffs
biospace
3d
Foghorn cuts 40% of workforce
biospace
7d
6 immunology targets to sustain a mammoth I&I market
biospace
10d
Endpoints 11 2026 winner SonoThera has a new approach to non-viral gene therapy
endpoints
10d
J&J, Legend tout long-term survival benefits for Carvykti in multiple myeloma
biospace
10d
Indivior ends PAM drug collab with Addex ahead of Supernus merger
fiercebiotech
11d
The human cost of AI interviews
biospace
11d
Growth mode: 3 biotechs that are staffing up after series B raises
biospace
13d
Opinion: Former FDA commissioners: Heidi Overton has an opportunity to strengthen the FDA
stat
13d
An orexin drug’s ‘proof-of-concept’ in ADHD; Cue’s ‘unwarranted’ share slide
biopharma dive
14d
Boehringer, Envisagenics sign $1B multi-target oncology collaboration
fiercebiotech
14d
FDA approves ataxia-telangiectasia drug; Alkermes reports ADHD data
endpoints
14d
How J&J paved the way for Compass’ coming psychedelic drug launch
biopharma dive
14d
Beacon says gene therapy succeeds in key trial of rare eye disease XLRP
endpoints
14d
Retension and Lilly-backed TRex Bio both set out plans to join biotech IPO stampede
fiercebiotech
14d
Citing Replimune approval, experts say localized cancer meds could redefine care
biospace
15d
Beacon lights path to FDA approval with pivotal trial win for rare vision loss gene therapy
fiercebiotech
17d
Xenon tumbles on voluntary psychiatry hold, but analysts confident in $2B epilepsy opportunity
biospace
17d
BMS scraps Orum’s targeted degrader after reviewing Phase 1 data
biospace
17d
Medtronic earns FDA clearance for LigaSure use with its Hugo robotic system
fiercebiotech
18d
Chutes & Ladders—Legend poaches Novartis vet to boost commercial potential
fiercebiotech
18d
Rare EGFR mutation increases lung cancer risk 62 times in never smokers
fiercebiotech
19d
Deep dive: Psychedelics back on FDA’s doorstep
biospace
19d
5 biotechs braving the commercial waters with product launches
biospace
20d
FDA clears first generic radioligand drug; Sionna turns to layoffs
biopharma dive
20d
Stakeholders urge FDA to define data, treatment standards as psychedelic drugs near market
biospace
20d
Despite 3 patient deaths, Cullinan-Taiho plan FDA filing for lung cancer pill on survival benefit
biospace
20d
GSK bags Chimagen’s trispecific T cell engager in deal worth up to $750M
biospace
20d
Contineum, J&J's drug fails in mid-stage depression trial
endpoints
20d
Newly formed Jaguar acquires Afib device assets from J&J
fiercebiotech
← prev
page 1 of 6
next →
